The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases
This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …
Targeting the alternative bile acid synthetic pathway for metabolic diseases
W Jia, M Wei, C Rajani, X Zheng - Protein & cell, 2021 - academic.oup.com
The gut microbiota is profoundly involved in glucose and lipid metabolism, in part by
regulating bile acid (BA) metabolism and affecting multiple BA-receptor signaling pathways …
regulating bile acid (BA) metabolism and affecting multiple BA-receptor signaling pathways …
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
ME Rinella, BA Neuschwander-Tetri, MS Siddiqui… - Hepatology, 2023 - journals.lww.com
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
N Bougarne, B Weyers, SJ Desmet, J Deckers… - Endocrine …, 2018 - academic.oup.com
Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …
Novel therapeutic targets for cholestatic and fatty liver disease
M Trauner, CD Fuchs - Gut, 2022 - gut.bmj.com
Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …
Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—part 1: definition, risk factors and assessment
Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic
complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease …
complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease …
[PDF][PDF] Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives
JP Arab, SJ Karpen, PA Dawson, M Arrese… - …, 2017 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …
[HTML][HTML] Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription
factor belonging, together with PPARγ and PPARβ/δ, to the NR1C nuclear receptor …
factor belonging, together with PPARγ and PPARβ/δ, to the NR1C nuclear receptor …
[HTML][HTML] KASL clinical practice guidelines: management of nonalcoholic fatty liver disease
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …